Clinical trials
Systemic Sclerosis clinical trials
Below are recruiting systemic sclerosis clinical trials, each written for real people, not researchers. We’re tracking 165 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06888960RecruitingEarly Phase 1
Testing CC312 for people with autoimmune diseases
This early-phase study tests a new drug called CC312 in patients with certain autoimmune diseases like lupus, myositis, scleroderma, rheumatoid arthritis, immune thrombocytopenia, or autoimmune hemolytic anemia. The goal is to see if it's safe and how the body handles it.
Tianjin, ChinaAges 18 years+ - NCT07193810RecruitingEarly Phase 1
CC312 for autoimmune diseases that returned or didn't respond
This study tests a new treatment called CC312 for people with lupus, myositis, or scleroderma that hasn't gotten better with standard therapies. It aims to see if CC312 can help control the disease when other treatments have failed.
Deyang, SichuanAges 18–65 - NCT07085104RecruitingPhase 1
Study of ALLO-329 for lupus, myositis, or scleroderma
This trial tests a new one-time cell therapy (ALLO-329) made from donor cells to target and calm overactive immune cells in people with lupus, myositis, or scleroderma that hasn't improved with usual medications. It aims to see if this treatment is safe and can help reduce disease activity.
Phoenix, ArizonaAges 18–74 - NCT06732674Recruiting
Home-based care for lung disease in rheumatic conditions
This trial tests whether people with lung disease caused by a rheumatic condition can safely manage their care at home using a smartphone or tablet. It aims to see if home monitoring is as effective as in-person visits for keeping your lungs healthy.
OsloAges 18 years+ - NCT06614270Recruiting
CAR-NK cell therapy for severe autoimmune diseases
This trial tests a new type of immune cell therapy using modified natural killer cells (CAR-NK) that target a protein called CD19 and produce helpful signals (IL-10 and IL-15). It is for people with certain autoimmune diseases that have not improved with standard treatments or have come back after getting better.
Hangzhou, ZhejiangAges 18–65 - NCT06350110RecruitingPhase 1/Phase 2
CAR T cells for lupus
This trial tests a new type of CAR T cell therapy for people with active lupus that has not responded to other treatments. It uses specially engineered cells to target and eliminate certain immune cells that are causing the disease, with the goal of reducing symptoms and preventing flare-ups.
Beijing, Beijing MunicipalityAges 18–90 - NCT04402086Recruiting
Rheumatology patient and skin sample registry study at Yale
This study builds a health record and blood/skin sample collection for people with rheumatic autoimmune diseases who are getting care at Yale. It may help researchers understand these conditions and develop better tests or treatments over time.
New Haven, ConnecticutAges 18–99 - NCT04095351Recruiting
Study of connective tissue disease affecting the lungs
This study looks at people aged 18 and older who have a connective tissue disease and lung involvement. It aims to better understand how these lung problems progress and may help doctors choose better care.
InnsbruckAges 18–80 - NCT03269630Recruiting
Pulmonary hypertension biobank for heart-lung blood samples
This study collects and stores health information and possibly blood samples from people being evaluated for pulmonary hypertension or related autoimmune conditions. It helps researchers learn more about these illnesses and may support future studies.
New Orleans, LouisianaAges 18 years+ - NCT07543679Recruiting
Measuring Skin Damage in Systemic Sclerosis with a Skin Sensor
This study tests a sensor device called ADHELASKIN to see if it can accurately measure skin damage in people with systemic sclerosis (SSc), a condition that hardens and tightens the skin. The goal is to find a better way to track skin changes during the disease.
Saint-Priest-en-Jarez, Pays de la Loire RegionAges 18 years+ - NCT07491523Recruiting
Adding anti-fibrotic to immunosuppression for scleroderma lung disease
This trial is testing whether adding an anti-fibrotic drug (a medicine that fights scarring) to two immunosuppressive drugs works better than the two drugs alone for people with scleroderma-related lung disease.
PátraiAges 18 years+ - NCT07355972RecruitingEarly Phase 1
CT1195E cell therapy for progressive scleroderma
This trial tests a new cell therapy called CT1195E for people with refractory or progressive systemic sclerosis (scleroderma) that also affects the lungs. It aims to see if the treatment is safe and can help slow or stop the disease.
Wuhan, HubeiAges 18–60 - NCT07295847RecruitingPhase 1
Study of AZD0120 for autoimmune diseases
This trial tests if a new medication, AZD0120, is safe for people with autoimmune diseases. It aims to help patients by targeting the immune system.
Tucson, ArizonaAges 18–75 - NCT07284797RecruitingPhase 1
Safety study for autoimmune disease and healthy volunteers
This trial is testing an experimental drug for safety in people with certain autoimmune diseases—like myositis, scleroderma, or Sjögren's disease—as well as in healthy volunteers. It aims to find out if the drug is safe enough to study further.
MelbourneAges 18–75 - NCT07245238RecruitingPhase 3
CBD lotion for itching in scleroderma
This trial tests if a CBD (cannabidiol) lotion can help reduce itching in people with scleroderma, a condition that often causes chronic itch. It compares the CBD lotion to a placebo (inactive lotion) to see if it works and is safe.
Khon KaenAges 18–70 - NCT07228429Recruiting
Measuring calcium deposits in scleroderma with CT scans
This study will use CT scans to measure calcium deposits under the skin in people with scleroderma. It may help doctors better understand and track this condition.
New Haven, ConnecticutAges 18 years+ - NCT07184450RecruitingPhase 1
CAR-T cell therapy for children with hard-to-treat rheumatic diseases
This trial tests a new treatment using your child's own immune cells, modified to target B cells and fight severe rheumatic diseases like juvenile dermatomyositis, arthritis, scleroderma, or Sjogren's syndrome. It's for children who haven't improved with standard treatments.
Hangzhou, ZhejiangAges 5 years+ - NCT07183072Recruiting
Scleroderma: Physical Performance and Functionality Study
This study looks at how scleroderma affects physical performance and daily function in children and adults. It aims to understand the impact of the disease on movement and everyday activities.
Çankaya, AnkaraAges 7 years+ - NCT07182981Recruiting
Chewing and swallowing in scleroderma patients
This study looks at how scleroderma affects chewing and swallowing in children and adults. It aims to help understand these problems better so care can be improved.
Çankaya, AnkaraAges 7 years+ - NCT07167537RecruitingPhase 1
Study of OL-CD19-GDT for hard-to-treat autoimmune diseases
This trial tests a new treatment called OL-CD19-GDT for people with systemic sclerosis or Sjögren's syndrome that hasn't responded to standard therapies. It aims to see if the treatment is safe and might help control the disease.
BeijingAges 18–65 - NCT05892614RecruitingPhase 2
Efzofitimod for early systemic sclerosis lung scarring
This trial tests efzofitimod to see if it can improve or slow lung disease caused by systemic sclerosis (scleroderma), and to check safety and side effects. It focuses on people with relatively early disease and measurable lung involvement on lung scans.
Los Angeles, CaliforniaAges 18 years+ - NCT07000682RecruitingEarly Phase 1
UTAA91 injection for systemic sclerosis study
This trial tests a new treatment, UTAA91 injection, for people with moderate-to-severe systemic sclerosis that hasn't improved with standard therapies. It may offer an option when other treatments have failed or aren't available.
Wuhan, HubeiAges 18 years+ - NCT06991114RecruitingPhase 2
AlloNK and rituximab for relapsing rheumatologic diseases
This trial tests a new natural killer (NK) cell therapy called AlloNK given with rituximab for people with certain autoimmune diseases (rheumatoid arthritis, Sjögren's disease, inflammatory myopathies, or systemic sclerosis) that have not responded well to standard treatments. The goal is to see if this combination can better control the disease.
Tuscaloosa, AlabamaAges 18 years+ - NCT06947460RecruitingPhase 1/Phase 2
CAR-T cell therapy for resistant lupus, sclerosis, and Sjögren's lung disease
This trial tests a special immune cell therapy (CAR-T cells targeting CD19 and BCMA) for people with lupus nephritis, systemic sclerosis, or Sjögren's-related lung blood vessel disease that hasn't improved with usual treatments. The goal is to see if this one-time cell infusion can calm the overactive immune system and improve symptoms.
Beijing, China,BeijingAges 10–65
Hear when a new Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for systemic sclerosis?
- Yes. Clin2 currently lists 165 recruiting systemic sclerosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a systemic sclerosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a systemic sclerosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.